Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesICON PLC

ICON PLC

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
199.7 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
647162
Market Cap
26546.46M
P/E
38.87

Momentum Score

…

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
199.42
Low
208.38
High
52 Week Price Range
210.44
Low
344.77
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ICON plc is a global contract research organization that designs, manages and analyzes clinical trials for pharmaceutical, biotech and device sponsors. Long-term growth may be supported by rising R&D outsourcing, greater trial complexity and adoption of decentralized, data-driven trial methods, and the company appears positioned to benefit from its global footprint and integrated services.
Key investment risks include intense competition and pricing pressure in the CRO sector, delays or failures in client trials, regulatory changes that could reduce sponsor spending, and execution risks related to acquisitions and maintaining operational quality.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
199.70
Dividend Yield
-
Revenue TTM
8231.98M
Revenue Per Share
100.02
Gross Profit TTM
2218.74M
Debt / Equity
0.43
ROE
7.55%
Net Debt
3560.22M
ROCE
5.61%
Diluted EPS TTM
8.26

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 567.85M 196.68M 382.18M 426.99M 368.38M
Minority interest 0.00M 0.00M -0.63M 39.51M 39.51M
Net income 506.29M 153.19M 330.79M 373.99M 322.82M
Selling general administrative 778.75M 585.33M 341.69M 336.75M 325.79M
Gross profit 2214.34M 1508.21M 808.03M 831.70M 769.49M
Reconciled depreciation 569.51M 314.99M 66.13M 61.55M 65.92M
Ebit 795.24M 608.47M 391.97M 433.41M 381.06M
Ebitda 1437.93M 923.46M 488.88M 494.96M 446.98M
Depreciation and amortization 642.70M 314.99M 96.91M 61.55M 65.92M
Operating income 795.24M 608.47M 391.97M 433.41M 377.12M
Other operating expenses 6875.31M 4872.93M 2405.32M 2372.43M 2218.66M
Interest expense 229.73M 182.42M 15.07M 6.42M 13.61M
Tax provision 59.41M 41.33M 47.88M 51.13M 41.96M
Interest income 2.35M 0.57M 2.72M 6.86M 4.76M
Net interest income -227.39M -181.85M -10.29M -6.42M -8.74M
Income tax expense 59.41M 41.33M 50.75M 51.13M 45.56M
Total revenue 7741.39M 5480.83M 2797.29M 2805.84M 2595.78M
Total operating expenses 1348.27M 900.32M 416.06M 398.30M 392.37M
Cost of revenue 5527.05M 3972.61M 1989.26M 1974.13M 1826.29M
Total other income expense net -227.39M -411.79M -9.79M -6.42M 0.92M
Net income from continuing ops 505.30M 153.19M 332.96M 375.86M 322.66M
Net income applicable to common shares 505.30M 153.19M 327.81M 368.94M 322.66M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 16989.86M 17185.28M 17387.09M 3465.80M 2907.51M
Intangible assets 3855.86M 4278.66M 4710.84M 66.46M 67.89M
Other current assets 132.10M 137.09M 114.32M 53.48M 41.52M
Total liab 7749.12M 8687.32M 9320.26M 1585.13M 1289.46M
Total stockholder equity 9240.74M 8497.96M 8066.83M 1880.67M 1618.06M
Other current liab 892.95M 1046.81M 1009.06M 402.10M 362.25M
Common stock 6.70M 6.65M 6.64M 4.58M 4.63M
Capital stock 6.70M 6.65M 6.64M 4.58M 4.63M
Retained earnings 2433.72M 1821.38M 1416.08M 1389.98M 1110.23M
Other liab - 1266.03M 1300.68M 52.15M 42.10M
Good will 9022.08M 8971.67M 9037.93M 936.26M 883.17M
Other assets - 169.10M 137.59M 50.71M 51.35M
Cash 378.10M 288.77M 752.21M 840.30M 520.31M
Total current liabilities 2825.61M 2690.60M 2478.94M 1138.48M 1131.25M
Current deferred revenue 1654.51M 1507.45M 1323.96M 660.93M 366.99M
Net debt 3560.22M 4497.06M 4843.58M -406.69M -65.76M
Short term debt 146.56M 55.15M 55.15M 24.33M 377.96M
Short long term debt 110.15M 55.15M 55.15M - 349.64M
Short long term debt total 3938.32M 4785.83M 5595.80M 433.61M 454.55M
Other stockholder equity 6942.67M 6841.47M 6735.04M 499.11M 579.01M
Property plant equipment - 504.15M 534.57M 258.90M 270.06M
Total current assets 3411.47M 3229.07M 2941.20M 2114.08M 1624.98M
Long term investments 46.80M 32.63M 24.96M 20.30M 10.05M
Net tangible assets - -4752.37M -5681.95M 847.52M 666.99M
Short term investments 1.95M 1.71M 1.71M 1.73M 49.63M
Net receivables 2899.31M 2801.49M 2072.95M 1224.78M 1013.53M
Long term debt 3665.44M 4599.04M 5381.16M 348.48M -
Inventory 0.00M 7.06M 5.80M 4.81M 3.20M
Accounts payable 131.58M 81.19M 90.76M 51.11M 24.05M
Accumulated other comprehensive income -142.34M -171.54M -90.94M -13.00M -75.82M
Common stock total equity - - - 4.58M 4.63M
Non currrent assets other 78.47M 92.17M 89.19M 26.90M 34.67M
Non current assets total 13578.39M 13956.21M 14445.89M 1351.72M 1282.53M
Capital lease obligations 162.74M 131.64M 159.48M 85.14M 104.91M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -163.03M -145.87M -6.01M -46.58M -162.03M
Change to liabilities - 192.94M -69.12M 318.33M 90.01M
Total cashflows from investing activities - -145.87M -6024.23M -46.58M -162.03M
Net borrowings - -800.00M 5027.32M 5027.32M 5027.32M
Total cash from financing activities -844.04M -864.17M 5114.73M -235.02M -125.41M
Change to operating activities - 10.12M 108.26M -26.93M -16.15M
Net income 612.34M 505.30M 153.19M 331.43M 375.86M
Change in cash 89.33M -463.44M -88.09M 320.00M 124.46M
Begin period cash flow 288.77M 752.21M 840.30M 520.31M 395.85M
End period cash flow 378.10M 288.77M 752.21M 840.30M 520.31M
Total cash from operating activities 1161.03M 563.32M 829.14M 594.72M 412.54M
Depreciation 627.50M 569.51M 314.99M 95.07M 61.55M
Other cashflows from investing activities - - -10.00M -10.00M -111.38M
Dividends paid - 35.83M - 13.19M -
Change to inventory - - - -1.63M -69.70M
Change to account receivables -78.58M -420.69M 113.51M -175.04M -101.55M
Sale purchase of stock 0.00M -99.98M -99.98M -175.00M -146.93M
Other cashflows from financing activities -0.02M 110.81M 5874.77M 320.48M -0.11M
Change to netincome - 20.97M 213.09M 31.73M 28.84M
Capital expenditures 140.69M 142.16M 93.75M 51.05M 50.65M
Change in working capital -114.82M -550.22M 135.00M 114.71M -82.74M
Stock based compensation 55.67M 70.52M 133.84M 26.27M 26.82M
Other non cash items 65.76M 93.18M 152.75M -23.83M 32.60M
Free cash flow 1020.34M 421.15M 735.39M 543.67M 361.90M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ICLR
ICON PLC		 -
-%		 199.70 38.87 20.58 3.11 2.73 3.55 18.94
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

ICON PLC

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

South County Business Park, Dublin, Ireland, D18 X5R3

353 1 291 2000

https://www.iconplc.com

41150

Name Title Year Born
Dr. Steven A. Cutler MBA, Ph.D. CEO & Director 1960
Mr. Brendan Brennan Chief Financial Officer 1979
Jonathan Curtain Sr. VP of Corp. & Commercial Fin. NA
Mr. Thomas N. O'Leary Chief Information Officer NA
Mr. Diarmaid Cunningham Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. 1975
Ms. Niamh Murphy Director of Corp. Communications NA
Mr. David Green VP of Marketing NA
Mr. Joe Cronin Chief HR Officer NA
Mr. Simon Holmes Pres of Corp. Investments & Partnerships 1967
Ms. Dana Lynn Poff Snr. Exec. VP of Program Management NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…